Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

506.51 -3.25 (-0.64%)
Streaming Delayed Price Updated: 12:52 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 190,278
Open 507.06
Bid (Size) 505.50 (80)
Ask (Size) 507.00 (40)
Prev. Close 509.76
Today's Range 505.05 - 520.86
52wk Range 277.64 - 615.00
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-14.7%
-14.7%
1 Month
-3.4%
-3.4%
3 Month
+9.7%
+9.7%
6 Month
-16.0%
-16.0%
1 Year
+77.7%
+77.7%

More News

Read More
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
Via The Motley Fool
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth ↗
Via Chartmill
Topics Earnings
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗
Via Chartmill
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗
Via Stocktwits
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Madrigal (MDGL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Via The Motley Fool
News headline image
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗
Via The Motley Fool
News headline image
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
Via The Motley Fool
Topics Bankruptcy
News headline image
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗
Via The Motley Fool
News headline image
2 Predictions for Novo Nordisk in 2026 ↗
Via The Motley Fool

Frequently Asked Questions

Is Madrigal Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Madrigal Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Madrigal Pharmaceuticals, Inc. - Common Stock trade on?
Madrigal Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock is MDGL on the Nasdaq Stock Market
What is the current price of Madrigal Pharmaceuticals, Inc. - Common Stock?
The current price of Madrigal Pharmaceuticals, Inc. - Common Stock is 506.51
When was Madrigal Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Madrigal Pharmaceuticals, Inc. - Common Stock was at 06/25/26 12:52 PM ET
What is the market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock is 8.66B
How many shares of Madrigal Pharmaceuticals, Inc. - Common Stock are outstanding?
Madrigal Pharmaceuticals, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.